Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
- Conditions
- Interventions
- Drug: VenetoclaxDrug: NavitoclaxDrug: DexamethasoneDrug: VincristineDrug: Calaspargase PegolDrug: DasatinibDrug: LeucovorinDrug: CytarabineDrug: Intrathecal TriplesBiological: BlinatumomabDrug: PegaspargaseDrug: MethotrexateDrug: Erwinia asparaginaseDrug: MercaptopurineDrug: CyclophosphamideDrug: EtoposideRadiation: Radiation
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05192889
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- LLS PedAL Initiative, LLC
- Target Recruit Count
- 98
- Registration Number
- NCT05183035
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Alliance for Childhood Diseases dba Cure 4 The Kids Foundation, Las Vegas, Nevada, United States
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Chen Suning
- Target Recruit Count
- 188
- Registration Number
- NCT05177731
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT05157971
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRecurrent Myelodysplastic SyndromeRefractory Mixed Phenotype Acute LeukemiaDown SyndromeMyelodysplastic Syndrome Post Cytotoxic TherapyRecurrent Mixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT05146739
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- LanZhou University
- Target Recruit Count
- 30
- Registration Number
- NCT05053425
- Locations
- 🇨🇳
Long Zhao, Lanzhou, Gansu, China
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
- Conditions
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT05049473
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
🇪🇸ICO-Hospital Duran i Reynals, Bellvitge, Spain
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT05032183
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 22
- Registration Number
- NCT05024552
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Kronos Bio
- Target Recruit Count
- 15
- Registration Number
- NCT05020665
- Locations
- 🇺🇸
Mount Sinai Health System, New York, New York, United States
🇫🇷Hôpital Côte De Nacre, Caen, Calvados, France
🇺🇸Hollings Cancer Center, Charleston, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.